MARKET

ADVM

ADVM

Adverum
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.92
+1.75
+14.38%
After Hours: 13.94 +0.02 +0.14% 19:12 01/20 EST
OPEN
13.26
PREV CLOSE
12.17
HIGH
14.79
LOW
13.18
VOLUME
2.47M
TURNOVER
--
52 WEEK HIGH
26.98
52 WEEK LOW
7.36
MARKET CAP
1.36B
P/E (TTM)
-10.8963
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Adverum jumps 16% after insider transactions
Adverum Biotechnologies (ADVM) is trading 15.9% higher today after the company disclosed in regulatory filings that CEO Laurent Fischer and Chairman Patrick Machado together bought 18.6K of its common stock in total.With the purchase
Seekingalpha · 9h ago
Wednesday 1/20 Insider Buying Report: VGR, ADVM
Jan 20, 2021 (MarketNewsVideo.com via COMTEX) -- As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to...
MarketNewsVideo.com · 13h ago
Insider Trends: Adverum Biotechnologies Insider 90-Day Buying Trend Prolonged with Purchase
MT Newswires · 1d ago
All You Need to Know About Adverum Biotechnologies (ADVM) Rating Upgrade to Buy
Zacks · 01/11 17:00
Adverum Biotechnologies Completes Patient Enrollment for INFINITY Phase 2 Trial of ADVM-022 in DME and Provides 2021 Business Outlook
-- INFINITY Phase 2 trial fully enrolled; data expected in 2H21 --
GlobeNewswire · 01/11 13:00
8-K: Adverum Biotechnologies, Inc.
(EDGAR Online via COMTEX) -- false 0001501756 0001501756 2021-01-08 2021-01-08 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 01/11 12:10
Wet Age Related Macular Degeneration (AMD) Market : Facts, Figures and Analytical Insights 2021-2027
Jan 11, 2021 (Market Insight Reports) -- The Wet Age Related Macular Degeneration (AMD) Market report is a compilation of first-hand information, qualitative...
Market Insight Reports · 01/11 11:10
Implied Volatility Surging for Adverum Biotechnologies (ADVM) Stock Options
Investors need to pay close attention to Adverum Biotechnologies (ADVM) stock based on the movements in the options market lately.
Zacks · 01/08 13:49
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ADVM. Analyze the recent business situations of Adverum through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ADVM stock price target is 25.22 with a high estimate of 36.00 and a low estimate of 13.00.
EPS
Institutional Holdings
Institutions: 215
Institutional Holdings: 105.53M
% Owned: 108.26%
Shares Outstanding: 97.48M
TypeInstitutionsShares
Increased
65
16.76M
New
49
1.11M
Decreased
38
3.83M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.31%
Pharmaceuticals & Medical Research
-0.03%
Key Executives
Chairman/Independent Director
Patrick Machado
Chairman/Independent Director
C. Patrick Machado
President
Leone Patterson
Chief Executive Officer/Director
Laurent Fischer
Chief Financial Officer
Thomas Leung
Chief Technology Officer
Angela Thedinga
Vice President
Heikki Jouttijarvi
Vice President
Thomas Kochy
Vice President
Christopher Morrison
Other
Aaron Osborne
Other
Peter Soparkar
Director
Mehdi Gasmi
Independent Director
Eric Carter
Independent Director
Rekha Hemrajani
Independent Director
Mark Lupher
Independent Director
James Scopa
Independent Director
Richard Spivey
Independent Director
Dawn Svoronos
Independent Director
Scott Whitcup
Independent Director
Thomas Woiwode
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ADVM
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company targeting unmet medical needs for serious ocular and rare diseases. The Company is evaluating its gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of its lead indication, wet age-related macular degeneration. It has collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products (AVA-311) for ophthalmic diseases. The Company develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its capabilities include clinical development, vector discovery, and in-house manufacturing, specifically in process development, assay development and current Good Manufacturing Practices (cGMP) quality control.
More

Webull offers kinds of Adverum Biotechnologies Inc stock information, including NASDAQ:ADVM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADVM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADVM stock methods without spending real money on the virtual paper trading platform.